Dr. Eyal Greenberg CEO and Scientific Co-founder of 4C Biomed. Experienced in project management and establishment of high-throughput screening platforms. Broad experience in integrative platforms, including cell biology, genetics, immunology and bioinformatic interfaces.
Prior to establishing 4C Biomed, Eyal Greenberg served as Chief Operating Officer, Researcher and Team Leader at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. Eyal holds a B.Sc. in Life Sciences, M.Sc. in Biotechnology and Ph.D. in Clinical microbiology and Immunology from Tel Aviv University. In addition, Eyal holds a Master of Business Administration from Bar Ilan University. He is the author of multiple peer-reviewed papers and has won several awards.
CEO
Michael Hennig studied Physics and Biochemistry, received the Ph.D. in structural biology at EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed two years postdoc work at the Biozentrum, University of Basel, Switzerland. He is author of more than 80 scientific peer reviewed paper and, since 2011, guest professor in structural biology at the University of Basel.
He worked 20 years in pharmaceutical industry at Roche, Basel, Switzerland in various positions and finally Global Head and Principle Leader of discovery technologies with responsibility for structure-based drug discovery, protein science, assay development and HTS, Roche corporate compound library, stem cell platform and analytical physical methods. In 2015, he co-founded leadXpro, a corporation dedicated to structure-based drug discovery for membrane protein targets (GPCR’s, Ion-channels, Transporter) and utilizing most advanced technologies such as the X-ray free electron laser (at PSI, SwissFEL) and cryo-electron microscopy (at University of Basel, cryo-EM).
Founder & CEO
Edith LECOMTE NORRANT has a PhD and HDR in Chemical Engineering, with 6 years of experience as National Researcher in CNRS (Public Research in France) and more than 20 years of experiences in private biopharmaceutical companies, Rhône Poulenc (Ex SANOFI), Pierre Fabre, and UCB Biopharmaceutical on an international scale (Europe, US, South America, ...).
She founded IPSOMEDIC in July 2019 in order to implement the numerous ideas she developed over the years. Her ambition is to provide innovative solutions for the development and industrialisation of chemical and biological compounds in a green and safe manner. This would be a first step towards her vision of personalised medicalisation.
CEO
Pascal Mayer is a scientific innovator and inventor of various technologies with large market value. His inventions lead to the filing of 12 patent families including the core patents behind the world's leading sequencing technology (Illumina), and biofilm measurement technologies (Biofilm Control). Prior to Alphanosos, key experience included VP drug-discovery at BioFilm Control, CEO at Haploys, CSO at Manteia Predictive Medicine (a spin-off from Serono), and Scientist at Glaxo-Wellcome and later Serono.
Research Scientist
Thomas Evangelidis is a Senior Researcher in the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague and CEITEC in Brno. He has 12 years of experience in novel method and software development for protein-ligand binding affinity prediction and NMR structure determination, for which he combines notions from Chemoinformatics, Machine Learning, and Quantum Chemistry. He is currently starting a spin-off company named "AIffinity", which will provide software and computational services for Molecular Binding Affinity prediction by AI and 4D NMR structure determination.
Thomas obtained his PhD in Computation Medicinal Chemistry & NMR from the Dept. of Pharmacy,
University of Athens, Greece & Central European Institute of Technology (CEITEC), Brno, Czech Republic. He continued in CEITEC for a 2-year post-doc on 4D-NMR protein structure determination. In 2018 he also joined IOCB, where he develops new methods for protein-ligand binding affinity prediction.
Founder & CEO
Founder & Chief Executive Officer (CEO),ImmuneBiotech. Exploring ways to induce termination of chronic inflammatory disorders by introducing novel and innovative immunotherapies. Consulting and CRO-related services.
Senior researcher, Lund University
Performed research work in the field of Medical Inflammation Research since 1997 in areas of: Chronic inflammation, Autoimmunity, Microbiology & Probiotics, Cancer & Inflammation.
University lecturer, Lund University. Teaching immunology, for the advance and the basic courses (2001-current). Also started 3 new basic courses in immunology incorporated in different programs.
Specialties: Chronic inflammation, Autoimmune disorders e.g. Multiple Sclerosis, Rheumatoid Arthritis, Type 1 Diabetes and Sjogren´s syndrome, Microbiology and probiotics: health benefits and related anti inflammatory effects, Biological markers, New drug target discovery, Drug delivery technology, Diagnosis, Cancer and inflammation.
Director
Dr Philip Beer is a physician scientist and precision oncology specialist who holds diverse roles across the healthcare, academic and commercial sectors. Philip provides clinical cancer genomics support to healthcare improvement projects, including the NHS, and to drug discovery and development ventures in academia and industry. Philip is part of the International Cancer Genome Consortium (ICGC) management team, the Friends of Cancer Research TMB working group and the forthcoming Precision FDA TMB challenge. These projects are unified by a singular goal of leveraging genomic technologies to improve outcomes for cancer patients, and are underpinned by a portfolio of research focused on linking cancer biology and genomics, delivered through honorary positions at the Sanger Institute, UK, and Mayo Clinic, USA.
Founder & CEO
Neuroscientist and social entrepreneur with nearly 20 years of experience in turning data into knowledge that can change lives in academic, industry and startup settings. After nearly losing a family member to depression, he decided to set up BRAINCURES to passionately enable better treatments and prevention of brain diseases that affect at least 1 in 10 people worldwide. The BRAINCURES Discovery Engine (BDE) Platform algorithms can deliver at least 6 fold higher drug discovery success rates and shorten the 12 year development life cycle by at least 4 years without deep learning steps associated with trendy artificial intelligence (AI) techniques. The biology powered technology has been recognized by invitations to speak worldwide and the Beanstalks 2017 Best Mental Health Startup Award. www.braincures.com
GET EXPERIENCE
Learn from the industry’s top leading professionals. Increase your knowledge and partners under one roof
09.00 - 09.30 AM
Drug Target Prediction and Repositioning using an integrated network – based approach
09.30 - 10.00 Am
Enabling novel therapeutic modalities with bispecific and
multi-specific antibodies
09.00 - 09.30 Am
Impact of formulation in drug delivery and drug efficacy
and safety
09.30 - 10.00 Am
Artificial Intelligence Modifies Drug Discovery
The Sponsorship opportunity at Meridian Drug Discovery come with countless benefits.
Meetings, meet with industry's most renowned decision-makers exclusively. Dine and discuss business in a private setting; competitor friendly atmosphere.
1The exhibition, deliver yourself from the irrelevant audience, surround yourself with the right decision-makers in a business-driven environment; choose quality over quantity.
3Presentation, Devote yourself to science, feed the next generation with experience-based knowledge. Grasp the opportunity to apprise yourself and your organization.
2Networking, a new partner, the next funding, is just one introduction away. introduce yourself to the right people in the right place. Initiate a new business relationship by being in the right place at the right time.
4
